DCVax-l treatment effect upon crossover.
Temodar (chemotherapy) is stopped upon progression which happens at around a little over half a year, typically. Temodar softens the tumor up by causing more mutations for DCVax-l monotherapy to target after Temodar treatment completion. Science has learned that Temodar reduces efficacy of t-cells, so it comes as no surprise, in some cases, that DCVax-l has more impact by itself against weakened tumor cells after Temodar is halted, because DCVax-l essentially initiates the production of brand new targeted t-cells that will not be incapacitated by Temodar (chemotherapy).
Think of it like this. Temodar mutates tumor cells for a little while (by interfering with tumor cell dna repair), but Temodar weakens the immune system’s t-cells, it’s a wash after a certain period, but add DCVax-l during or after Temodar therapy is finished, and you minimize Temodar’s negative impact but leverage its temporary positive impact. Meanwhile DCVax-l trained t-cells are far more heterogenous and thus able to recognize various tumor cell phenotypes whilst not being slowed by Temodar’s debilitating t-cell impact.
Market Data 
Markets 
AI
